Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Debt: 2009-2025

Historic Total Debt for Northwest Biotherapeutics (NWBO) over the last 15 years, with Sep 2025 value amounting to $16.9 million.

  • Northwest Biotherapeutics' Total Debt fell 43.61% to $16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year decrease of 43.61%. This contributed to the annual value of $22.0 million for FY2024, which is 25.51% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Total Debt stood at $16.9 million for Q3 2025, which was down 7.80% from $18.3 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Total Debt ranged from a high of $358.6 million in Q1 2021 and a low of $16.6 million during Q1 2025.
  • In the last 3 years, Northwest Biotherapeutics' Total Debt had a median value of $22.0 million in 2024 and averaged $22.7 million.
  • In the last 5 years, Northwest Biotherapeutics' Total Debt skyrocketed by 2,861.82% in 2021 and then crashed by 78.68% in 2023.
  • Over the past 5 years, Northwest Biotherapeutics' Total Debt (Quarterly) stood at $131.9 million in 2021, then plummeted by 34.40% to $86.5 million in 2022, then slumped by 65.92% to $29.5 million in 2023, then decreased by 25.51% to $22.0 million in 2024, then crashed by 43.61% to $16.9 million in 2025.
  • Its Total Debt stands at $16.9 million for Q3 2025, versus $18.3 million for Q2 2025 and $16.6 million for Q1 2025.